Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO

The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.